HK1116660A1 - Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency bmp - Google Patents

Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency bmp

Info

Publication number
HK1116660A1
HK1116660A1 HK08105989.4A HK08105989A HK1116660A1 HK 1116660 A1 HK1116660 A1 HK 1116660A1 HK 08105989 A HK08105989 A HK 08105989A HK 1116660 A1 HK1116660 A1 HK 1116660A1
Authority
HK
Hong Kong
Prior art keywords
bmp
mediated
treat
antagonists
iron
Prior art date
Application number
HK08105989.4A
Other languages
English (en)
Inventor
Herbert Y Lin
Jodie Babitt
Raymond T Chung
Tarek A Samad
Alan L Schneyer
Clifford Woolf
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1116660(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HK1116660A1 publication Critical patent/HK1116660A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK08105989.4A 2005-02-16 2008-05-28 Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency bmp HK1116660A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65347905P 2005-02-16 2005-02-16
PCT/US2006/005367 WO2006088972A2 (en) 2005-02-16 2006-02-16 Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism

Publications (1)

Publication Number Publication Date
HK1116660A1 true HK1116660A1 (en) 2009-01-02

Family

ID=36917026

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08105989.4A HK1116660A1 (en) 2005-02-16 2008-05-28 Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency bmp
HK16106934.8A HK1218875A1 (zh) 2005-02-16 2016-06-16 拮抗劑以調節鐵調素介導的鐵代謝的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16106934.8A HK1218875A1 (zh) 2005-02-16 2016-06-16 拮抗劑以調節鐵調素介導的鐵代謝的用途

Country Status (7)

Country Link
US (6) US7968091B2 (xx)
EP (3) EP1858541B1 (xx)
JP (4) JP5063366B2 (xx)
CA (1) CA2597925A1 (xx)
ES (2) ES2547866T3 (xx)
HK (2) HK1116660A1 (xx)
WO (1) WO2006088972A2 (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1392345B2 (en) 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2006012627A2 (en) 2004-07-23 2006-02-02 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
JP5063366B2 (ja) * 2005-02-16 2012-10-31 ザ ジェネラル ホスピタル コーポレイション ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
US20070099245A1 (en) * 2005-09-29 2007-05-03 Boris Gorovits Assays for neutralizing antibodies
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
JP5261187B2 (ja) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
EA035911B1 (ru) 2006-12-18 2020-08-31 Акселерон Фарма Инк. Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI480048B (zh) 2007-02-01 2015-04-11 Acceleron Pharma Inc 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN104548056B (zh) 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT3494986T (pt) 2008-08-14 2020-07-14 Acceleron Pharma Inc Armadilhas para gdf
CA2742871C (en) * 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
WO2010059861A1 (en) * 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
KR20120028358A (ko) 2009-06-12 2012-03-22 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
CA2825163C (en) * 2011-01-19 2019-12-03 Ferrumax Pharmaceuticals, Inc. Compositions for regulating iron homeostasis and methods of using same
AU2012352168C1 (en) 2011-12-14 2018-01-25 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2855570A1 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
RS57603B1 (sr) 2012-01-27 2018-11-30 Abbvie Deutschland Sastav i metod za dijagnozu i tretiranje bolesti povezanih sa degeneracijom neurita
EP2914619B1 (en) * 2012-11-01 2019-05-29 The Regents of The University of California Erythroferrone and erfe polypeptides and methods of regulating iron metabolism
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
EP2976085A1 (en) * 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
CN105659087B (zh) * 2013-06-13 2019-09-17 比奥德赛公司 筛选靶向靶生物实体的候选生物实体的方法
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
PT3227675T (pt) 2014-12-03 2023-05-30 Celgene Corp Antagonistas da ativina-actrii e utilizações para tratamento da síndrome mielodisplásica
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US11124766B2 (en) * 2015-06-12 2021-09-21 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
CA3054135A1 (en) 2016-02-22 2017-08-31 Brigham Young University Method and compositions for the treatment of anemia through the inhibition of furin
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR20240027854A (ko) 2017-03-02 2024-03-04 내셔날 리서치 카운실 오브 캐나다 Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
AU2020356575A1 (en) * 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US20220372136A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
WO2022098821A1 (en) * 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DK0414297T3 (da) 1989-08-11 1997-07-07 Genencor Int Effektiv fremstilling af mutantproteaser
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
WO1994024314A1 (en) 1993-04-19 1994-10-27 Kauffman Stuart A Random chemistry for the generation of new compounds
NZ276860A (en) 1993-11-02 1997-09-22 Affymax Tech Nv Apparatus and its use for synthesising diverse molecular products on substrates
AU6267098A (en) 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
EP1396543A3 (en) 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
AU2001237958A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. 22 human secreted proteins
WO2002077006A1 (en) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6800455B2 (en) 2000-03-31 2004-10-05 Scios Inc. Secreted factors
CN1159063C (zh) * 2000-06-21 2004-07-28 中国医学科学院血液学研究所 骨形态发生蛋白（bmp）作为治疗急性再生障碍性贫血药物的应用
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1392345B2 (en) * 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2003000461A1 (fr) 2001-06-21 2003-01-03 Meiyu-Giken Co., Ltd. Procede de polissage de la surface d'extremite de connexion d'un connecteur a fibres optiques, structure optique et structure heterogene coaxiale de couches de materiau, et dispositif de polissage
AU2002354803A1 (en) 2001-07-05 2003-01-21 Incyte Genomics, Inc. Secreted proteins
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
AU2003234136A1 (en) 2002-04-18 2003-11-03 The General Hospital Corporation Drg11-responsive (dragon) gene family
WO2004003150A2 (en) 2002-06-26 2004-01-08 Yale University Modulators and modulation of the interacton between rgm and neogenin
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
JP2006523440A (ja) * 2003-04-15 2006-10-19 ゼノン ファーマスーティカルス，インコーポレイテッド 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
JP5063366B2 (ja) * 2005-02-16 2012-10-31 ザ ジェネラル ホスピタル コーポレイション ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin

Also Published As

Publication number Publication date
US20170183411A1 (en) 2017-06-29
JP2012126722A (ja) 2012-07-05
JP2008530222A (ja) 2008-08-07
US20080260736A1 (en) 2008-10-23
US8637023B2 (en) 2014-01-28
US20120258105A1 (en) 2012-10-11
US8865168B2 (en) 2014-10-21
EP2335719B1 (en) 2015-06-24
CA2597925A1 (en) 2006-08-24
EP1858541A2 (en) 2007-11-28
EP1858541B1 (en) 2012-07-25
JP6073833B2 (ja) 2017-02-01
JP2014159478A (ja) 2014-09-04
WO2006088972A3 (en) 2007-04-19
EP2954903A1 (en) 2015-12-16
US20150072927A1 (en) 2015-03-12
JP5852426B2 (ja) 2016-02-03
JP5063366B2 (ja) 2012-10-31
WO2006088972A2 (en) 2006-08-24
JP6250764B2 (ja) 2017-12-20
US7968091B2 (en) 2011-06-28
ES2547866T3 (es) 2015-10-09
US8293236B2 (en) 2012-10-23
JP2016222716A (ja) 2016-12-28
HK1218875A1 (zh) 2017-03-17
US9556251B2 (en) 2017-01-31
US20120064076A1 (en) 2012-03-15
ES2392096T3 (es) 2012-12-04
US20130149304A1 (en) 2013-06-13
EP2335719A1 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
HK1116660A1 (en) Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency bmp
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
HK1220839A1 (zh) 內容的分發
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
HK1199874A1 (en) Spiro-oxindole compounds and their uses as therapeutic agents
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
SI1791791T1 (sl) Postopki in sestavki za obdelavo vode
EP1758450A4 (en) IMPROVEMENTS AT BZW. REGARDLESS PLANT TREATMENT AGENTS
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
EP1959931A4 (en) COMPOSITIONS AND METHODS FOR THE DERMAL TREATMENT OF PAIN
SI2185581T1 (sl) Postopki in sestavki, uporabni v zdravljenju mukozitisa
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
PL2318033T3 (pl) Kompozycje do leczenia bólu i/lub stanu zapalnego
EP1932346A4 (en) DISTRIBUTION OF CONTENT
GB0403269D0 (en) Improvements in or relating to the treatment of waste
PL1800589T3 (pl) Zmywarka do naczyń oraz sposób dostarczania wody do zmywarki do naczyń
PL2185581T3 (pl) Sposoby i kompozycje użyteczne do leczenia zapalenia błony śluzowej
EP1704871A4 (en) IRON COMPLEMENT AND USE
EP1926824A4 (en) METHOD FOR DETERMINING REACTIVITY TO ERYTROPOIETIN TREATMENT
EP1898921A4 (en) COMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS
EP1937064A4 (en) REGULATION OF MINERALS AND SKELETAL METABOLISM
IL185114A0 (en) Use of vitamin d compounds to treat endometriosis
PL1750507T3 (pl) Preparat do wywoływania zwiększonej produkcji związków biologicznie czynnych w roślinach oraz jego zastosowanie
GB0508094D0 (en) Improvements to showers and baths
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230216